Certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Canonical beta anomer; charge state depends on pH. |
| Molar mass | 334.22 g/mol | Calculated for the neutral formula. |
| CAS Registry Number | 1094-61-7 | Common identifier for beta-nicotinamide mononucleotide. |
| Appearance | White to off-white powder or crystals | Varies with purity, hydration, and polymorphism. |
| Solubility | Freely soluble in water; low solubility in nonpolar solvents | Reported values depend on salt form and temperature. |
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Quality control for NMN materials usually covers identity, assay purity, residual solvents, heavy metals, microbial limits, and moisture content. Certificates of analysis from suppliers may report high-performance liquid chromatography purity, mass spectrometry identity, and elemental impurity testing. Regulatory treatment differs by country: NMN is not an approved drug, and its status as a dietary supplement ingredient or novel food has been debated. Some authorities have restricted sales pending safety and regulatory review, while others allow it under specific categories. Buyers should verify documentation rather than rely on label claims.
Quantifying NMN requires methods that separate it from structurally similar compounds such as nicotinamide, nicotinamide riboside, and NAD+. Common approaches include high-performance liquid chromatography coupled with ultraviolet detection, liquid chromatography with tandem mass spectrometry, capillary electrophoresis, and nuclear magnetic resonance for identity confirmation. Because NMN is polar and often present at low concentrations in biological samples, sample preparation can involve protein precipitation, solid-phase extraction, or derivatization. Isotope-labeled internal standards help correct for matrix effects and recovery losses. Reported concentrations depend heavily on the matrix, extraction protocol, and analytical platform.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
Cachexia ( ) is a syndrome that occurs in people with certain illnesses, causing muscle loss that cannot be fully reversed with improved nutrition. It most commonly occurs in cases of cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS. These conditions change how the body handles inflammation, metabolism, and brain signaling. This can lead to muscle loss and other harmful changes to body composition over time. Unlike weight loss from inadequate caloric intake, cachexia mainly causes muscle loss and can happen with or without fat loss. Diagnosis of cachexia is difficult because there are no clear guidelines, and its occurrence varies from one affected person to the next. Like malnutrition, cachexia can lead to worse health outcomes and lower quality of life. The prognosis of patients with cachexia varies depending on the type and severity of the underlying illness, but is typically poor, especially with patients in late stages of disease. Cachexia can improve significantly with effective treatment of the underlying illness, but symptomatic treatment approaches such as nutritional therapy and exercise typically do not result in reversal of the syndrome, and have very limited benefit in advanced cases of cachexia.
== Mechanism of action == Strychnine is a neurotoxin which acts as an antagonist of glycine and acetylcholine receptors. It primarily affects the motor nerve fibers in the spinal cord which control muscle contraction. An impulse is triggered at one end of a nerve cell by the binding of neurotransmitters to the receptors. In the presence of an inhibitory neurotransmitter, such as glycine, a greater quantity of excitatory neurotransmitters must bind to receptors before an action potential is generated. Glycine acts primarily as an agonist of the glycine receptor, which is a ligand-gated chloride channel in neurons located in the spinal cord and in the brain. This chloride channel allows the negatively charged chloride ions into the neuron, causing a hyperpolarization which pushes the membrane potential further from threshold. Strychnine is an antagonist of glycine; it binds noncovalently to the same receptor, preventing the inhibitory effects of glycine on the postsynaptic neuron. Therefore, action potentials are triggered with lower levels of excitatory neurotransmitters. When the inhibitory signals are prevented, the motor neurons are more easily activated and the victim has spastic muscle contractions, resulting in death by asphyxiation. Strychnine binds the Aplysia californica acetylcholine binding protein (a homolog of nicotinic receptors) with high affinity but low specificity, and does so in multiple conformations.
=== Medications === The antifibrotics pirfenidone and nintedanib have been shown to slow the decline in lung function (as measured by forced vital capacity [FVC]) in those with ILD compared to placebo. Pirfenidone was associated with a 45% less decline in FVC at 52 weeks compared to placebo in a trial involving people with idiopathic pulmonary fibrosis, and was associated with a slower FVC decline in those with progressive pulmonary fibrosis. Nintedanib was also associated with a slower FVC decline and increased mean survival in people with ILD. The immunomodulator tocilizumab has a benefit in scleroderma associated ILD by helping to preserve lung function (as measured by FVC) at 48 weeks. The immunomodulators cyclophosphamide, mycophenolate mofetil and rituximab all showed improved lung function (as measured by % predicted FVC) compared to placebo in systemic sclerosis or scleroderma associated ILD. The inhaled vasodilator treprostinil (a synthetic prostacyclin which acts as a prostaglandin I2 analogue) is indicated in the treatment of pulmonary hypertension secondary to interstitial lung disease and is associated with improved exercise capacity as measured by a 6-minute walk test.
==== Comorbid personality disorders ==== Approximately 74% of individuals with BPD also fulfill criteria for another personality disorder during their lifetime, according to research published in 2008. The most prevalent co-occurring disorders are from Cluster A (paranoid, schizoid, and schizotypal personality disorders), affecting about half of those with BPD, with schizotypal personality disorder alone impacting one-third of individuals. Being part of Cluster B, BPD patients also commonly share characteristics with other Cluster B disorders (antisocial, histrionic, and narcissistic personality disorders), with nearly half of individuals with BPD showing signs of these conditions, and narcissistic personality disorder affecting roughly one-third. Cluster C disorders (avoidant, dependent, and obsessive-compulsive personality disorders) have the least comorbidity with BPD, with just under a third of individuals with BPD meeting the criteria for a Cluster C disorder.
Helium has a valence of zero and is chemically unreactive under all normal conditions. It is an electrical insulator unless ionized. As with the other noble gases, helium has metastable energy levels that allow it to remain ionized in an electrical discharge with a voltage below its ionization potential. Helium can form unstable compounds, known as excimers, with tungsten, iodine, fluorine, sulfur, and phosphorus when it is subjected to a glow discharge, to electron bombardment, or reduced to plasma by other means. The molecular compounds HeNe, HgHe10, and WHe2, and the molecular ions He+2, He2+2, HeH+, and HeD+ have been created this way. HeH+ is also stable in its ground state but is extremely reactive—it is the strongest Brønsted acid known, and therefore can exist only in isolation, as it will protonate any molecule or counteranion it contacts. This technique has also produced the neutral molecule He2, which has a large number of band systems, and HgHe, which is apparently held together only by polarization forces. Van der Waals compounds of helium can also be formed with cryogenic helium gas and atoms of some other substance, such as LiHe and He2. Theoretically, other true compounds may be possible, such as helium fluorohydride (HHeF), which would be analogous to HArF, discovered in 2000. Calculations show that two new compounds containing a helium-oxygen bond could be stable. Two new molecular species, predicted using theory, CsFHeO and N(CH3)4FHeO, are derivatives of a metastable FHeO− anion first theorized in 2005 by a group from Taiwan.
Sources: en.wikipedia.org
=== Protein === Protein HtrA2, also known as Omi, is a mitochondrially-located serine protease. The human protein Serine protease HTRA2, mitochondrial is 49kDa in size and composed of 458 amino acids. The peptide fragment of 1-31 amino acid is the mitochondrial transition sequence, fragment 32-133 amino acid is propertied, and 134-458 is the mature protein Serine protease HTRA2, mitochondrial, and its theoretical pI of this protein is 6.12. HtrA2 shows similarities with DegS, a bacterial protease present in the periplasm of gram-negative bacteria. Structurally, HtrA2 is a trimeric molecule with central protease domains and a carboxy-terminal PDZ domain, which is characteristic of the HtrA family. The PDZ domain preferentially binds C-terminus of the protein substrate and modulate the proteolytic activity of the trypsin-like protease domain.
Theraflu (made by Novartis) — previously contained pseudoephedrine, now contains phenylephrine Trima — contains 60 mg pseudoephedrine hydrochloride Tylol Hot (made by NOBEL İLAÇ SANAYİİ VE TİCARET A.Ş., Turkey) — a packet of 20 g contains 60 mg pseudoephedrine hydrochloride, 500 mg paracetamol and 4 mg chlorpheniramine maleate Unifed (made by United Pharmaceutical Manufacturer, Jordan) — contains pseudoephedrine hydrochloride (also triprolidine and guaifenesin). Zyrtec-D 12 Hour (made by McNeil Consumer Healthcare, a Kenvue company) — contains 120 mg pseudoephedrine hydrochloride (also 5 mg of cetirizine). Zephrex-D (made by Westport Pharmaceuticals) – a special meth-resistant form of pseudoephedrine that becomes gooey when heated.
The first step in the NADP-ME type C4 pathway is the conversion of pyruvate (Pyr) to phosphoenolpyruvate (PEP), by the enzyme Pyruvate phosphate dikinase (PPDK). This reaction requires inorganic phosphate and ATP plus pyruvate, producing PEP, AMP, and inorganic pyrophosphate (PPi). The next step is the carboxylation of PEP by the PEP carboxylase enzyme (PEPC) producing oxaloacetate. Both of these steps occur in the mesophyll cells: pyruvate + Pi + ATP → PEP + AMP + PPi PEP + CO2 → oxaloacetate PEPC has a low KM for HCO−3 — and, hence, high affinity, and is not confounded by O2 thus it will work even at low concentrations of CO2. The product is usually converted to malate (M), which diffuses to the bundle-sheath cells surrounding a nearby vein. Here, it is decarboxylated by the NADP-malic enzyme (NADP-ME) to produce CO2 and pyruvate. The CO2 is fixed by RuBisCo to produce phosphoglycerate (PGA) while the pyruvate is transported back to the mesophyll cell, together with about half of the phosphoglycerate (PGA). This PGA is chemically reduced in the mesophyll and diffuses back to the bundle sheath where it enters the conversion phase of the Calvin cycle. For each CO2 molecule exported to the bundle sheath the malate shuttle transfers two electrons, and therefore reduces the demand of reducing power in the bundle sheath.
The ambassador from the Netherlands explained his negative vote as being due to the reference in the preamble to the resolution "to potential harmful effects of the use of depleted uranium munitions on human health and the environment [which] cannot, in our view, be supported by conclusive scientific studies conducted by relevant international organizations." None of the other permanent members of the United Nations Security Council supported the resolution as China was absent for the vote, Russia abstained and the United States voted against the resolution. In September 2008, and in response to the 2007 General Assembly resolution, the UN Secretary General published the views of 15 states alongside those of the International Atomic Energy Agency (IAEA) and World Health Organization (WHO). The IAEA and WHO evidence differed little from previous statements on the issue. The report was largely split between states concerned about depleted uranium's use, such as Finland, Cuba, Japan, Serbia, Argentina, and predominantly NATO members, who do not consider the use of depleted uranium munitions problematic. In December 2008, 141 states supported a resolution requesting that three UN agencies: United Nations Environment Programme (UNEP), WHO and IAEA update their research on the impact of uranium munitions by late 2010—to coincide with the General Assembly's 65th Session, four voted against, 34 abstained and 13 were absent. As before Britain and France voted against the resolution.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ metabolism. It occurs naturally in cells and can also be produced synthetically for research or commercial use. Its name reflects its composition: nicotinamide, ribose, and a phosphate group.
NMN is a direct precursor in the NAD+ salvage pathway. NMNAT enzymes convert NMN and ATP into NAD+, a coenzyme used in many cellular reactions. This relationship makes NMN a focus of studies on NAD+ metabolism.
Small amounts of NMN have been reported in some plant foods, but measured levels vary and are not consistently quantified. Dietary contribution is generally considered minor compared with endogenous production. Food-matrix effects make accurate analysis difficult.
Common methods include HPLC with ultraviolet detection and LC-MS/MS. These techniques separate NMN from related nucleotides and quantify it by retention time and mass-to-charge ratio.